Otros idiomas Crossject

Acciones

En tiempo real Euronext Paris Otros sitios de cotización 13:34:21 08/07/2024			Varia. Cinco días.	Varia. 1 de enero.
1,674 ^EUR	-0,95 %		+3,46 %	-66,32 %

13/06	Crossject SA anuncia el nombramiento de Dan Chiche como Director Médico para Norteamérica	CI
05/06	Crossject: éxito de la ampliación de capital	CF

Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	27/06
Crossject : Document AMF CP. 2024DD982992	26/06
Crossject : Document AMF CP. 2024DD982993	26/06
Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.	26/06
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	26/06
Crossject : Document AMF CP. 2024DD982585	24/06
Crossject : Document AMF CP. 2024DD971458	17/06
Crossject SA Announces the Appointment of Dan Chiche as Chief Medical Officer North America	13/06
Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord	12/06
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America	12/06
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America	12/06
Crossject : Document AMF CP. 2024DD970268	10/06
Crossject : Document AMF CP. 2024DD970211	10/06
Crossject : Document AMF CP. 2024DD970091	10/06
Crossject : Document AMF CP. 2024DD970037	07/06
Webcast : résultats annuels 2023 et stratégie de développement	06/06
Crossject : succès de l'augmentation de capital	05/06
CROSSJECT : Succès de l'augmentation de capital	05/06
CROSSJECT : Success of the capital increase	05/06
Les marchés restent à l'horizontale	05/06

No hay resultados para esta búsqueda